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High-risk neuroblastoma, a predominantly TP53 wild-type (wt) tumour, is incurable in >50% patients supporting the use of
MDM2 antagonists as novel therapeutics. Idasanutlin (RG7388) shows in vitro synergy with chemotherapies used to treat
neuroblastoma. This is the first study to evaluate the in vivo efficacy of the intravenous idasanutlin prodrug, RO6839921
(RG7775), both alone and in combination with temozolomide in TP53 wt orthotopic neuroblastoma models. Detection of active
idasanutlin using liquid chromatography-mass spectrometry and p53 pathway activation by ELISA assays and Western analysis
showed peak plasma levels 1 h post-treatment with maximal p53 pathway activation 3–6 h post-treatment. RO6839921 and
temozolomide, alone or in combination in mice implanted with TP53 wt SHSY5Y-Luc and NB1691-Luc cells showed that
combined RO6839921 and temozolomide led to greater tumour growth inhibition and increase in survival compared to vehicle
control. Overall, RO6839921 had a favourable pharmacokinetic profile consistent with intermittent dosing and was well
tolerated alone and in combination. These preclinical studies support the further development of idasanutlin in combination
with temozolomide in neuroblastoma in early phase clinical trials.
Introduction
Long-term survival of high-risk neuroblastoma patients (met-
astatic disease over 1 year of age or MYCN amplified disease)
currently remains less than 50%, with those that survive often
suffering long-term side effects as a consequence of high-dose
intensive multimodal treatment.1 The identification of novel
therapies that improve survival and reduce toxicity is urgently
needed.
MDM2 antagonists are a novel class of anti-cancer agents
which, by disrupting the interaction between MDM2 and p53,
lead to stabilisation and activation of the p53 pathway and wt
p53 mediated tumour suppression through cell cycle arrest and
apoptosis.2 Idasanutlin (RO5503781/RG7388), a pyrrolidine
and second generation MDM2 antagonist from Hoffman-La
Roche has enhanced potency, selectivity and bioavailability,
and has been developed in both oral and intravenous
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(IV; RO6839921) formulations.3,4 To overcome tolerability
issues with daily administration, intermittent schedules of ida-
sanutlin, designed to enable bone marrow recovery, are being
clinically evaluated in adult cancers both alone and in
combination.5
TP53 mutations are rare in neuroblastoma even at relapse,
however upstream p53 pathway inactivation through MDM2
amplification (2.5–7%) and p14ARF abnormalities (2–22% homo-
zygous deletion; 7% methylation), have been reported particu-
larly at relapse and support the use of MDM2 antagonists.6–9
We and others have demonstrated highly potent anti-tumour
effects of idasanutlin in preclinical neuroblastoma models, alone
and in combination with chemotherapy currently used in the
treatment of high-risk neuroblastoma, namely cisplatin, doxoru-
bicin, topotecan (induction), busulfan (consolidation) and temo-
zolomide (relapse),10,11 and recently combinations with other
targeted agents have been reported.12,13 In addition, another
MDM2 antagonist in clinical trials, MI-773 (SAR405838), has
been shown to enhance doxorubicin mediated cytotoxicity in
neuroblastoma cell lines.14 To extend our original in vitro
observations,10 our study assessed RO6839921 the IV prodrug of
idasanutlin, alone and in combination with temozolomide,
equivalent to one cycle of treatment, in 2 orthotopic models of
neuroblastoma. RO6839921 (RG7775) is a pegylated IV prodrug
of idasanutlin, which is rapidly metabolised by blood esterases to
release active idasanutlin after administration, and was developed
to reduce the variability in exposure and dose-limiting gastroin-
testinal toxicity observed with oral idasanutlin, and for patients
unable to tolerate capsules.4,15,16 Temozolomide is an alkylating
agent which is part of standard backbone chemotherapy regi-
mens for relapsed and refractory neuroblastoma.17 The current
BEACON trial (ClinicalTrials.gov: NCT02308527) aims to test
whether temozolomide and irinotecan is superior to temozolo-
mide alone in the management of relapsed or refractory neuro-
blastoma. In our study we assessed the effect of temozolomide
alone and in combination with RO6839921 (RG7775) in 2 ortho-
topic models of neuroblastoma prior to clinical evaluation.
Materials and Methods
Chemicals, cell lines and growth inhibition assays
Idasanutlin and the IV prodrug RO6839921 were kindly pro-
vided by Hoffman-La Roche (Basel, Switzerland),3 and temo-
zolomide was purchased from Sigma-Aldrich (St. Louis, MO,
USA). For in vitro studies, idasanutlin and temozolomide were
dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich). For
in vivo studies, temozolomide was dissolved in PBS and clini-
cally formulated RO6839921 reconstituted in water, immedi-
ately prior to use. Human TP53 wt neuroblastoma cell lines
SHSY5Y (non-MYCN amplified) and NB1691 (MYCN and
MDM2 amplified) were retrovirally transduced with firefly
luciferase as previously described,18 generating SHSY5Y-Luc
and NB1691-Luc cell lines respectively. Cell lines were routinely
confirmed to be Mycoplasma negative using MycoAlert™
(Lonza, Basel, Switzerland) and independently authenticated by
multiplex short tandem repeat profiling by BMR Genomics
(Padova, Italy) and NewGene Limited (Newcastle upon
Tyne, UK) using Promega PowerPlex® Fusion System and
GenePrint® 10 System, respectively. Seventy-two hours growth
inhibition assays and median effect analysis were performed as
previously described.10
Orthotopic in vivo experiments
All in vivo experiments were approved by the licencing and
ethical committee of the IRCCS San Martino-IST (Genoa,
Italy), the Italian Ministry of Health, Newcastle University
and the UK Government Home Office. Orthotopic murine
SHSY5Y-Luc or NB1691-Luc models were established and
monitored using bioluminescence (BLI) IVIS imaging, as pre-
viously described.18–20 RO6839921 (equivalent to 100 mg/kg
of active idasanutlin) and temozolomide (34 mg/kg equivalent
to 100 mg/m2 were given by IV tail vein injection and oral
gavage, respectively. Tumour bearing mice were randomised
into n = 3/group and n = 8/group for pharmacokinetic (PK)/
pharmacodynamic (PD) studies and efficacy studies, respec-
tively, and samples taken at the indicated time points
(Supporting Information Fig. S1). To minimise esterase activ-
ity, 0.2% dichlorvos (Sigma-Aldrich) was added to blood sam-
ples. All animals received the complete schedule of treatment
without any signs of systemic toxicity. Animals were monitored
2–3 times weekly and euthanized humanely just before showing
signs of illness/suffering such as abdominal dilatation, paraple-
gia, dehydration, or severe weight loss. Percentage increase in
lifespan (%ILS) was calculated based on both median and mean
survival to humane endpoint, as previously described.5 For more
detailed procedures see Supporting Information.
Western blotting, macrophage inhibitory cytokine-1 (MIC-1)
ELISA assays and immunohistochemistry (IHC)
Tumours were disaggregated in Phosphosafe buffer (Merck
Millipore) using the Medimachine with Medicons inserts
What’s new?
Long-term survival of high-risk neuroblastoma patients currently averages than 50%. New therapies that both improve survival
and reduce treatment toxicity are urgently needed. MDM2 antagonists are a novel class of anti-cancer agents that stabilize the
p53 pathway and lead to tumour suppression. In this preclinical study, the authors tested a prodrug of the MDM2 inhibitor
idasanutlin in mice. They found that this compound inhibited tumour growth and increased survival, especially in combination
with temozolomide. These results support the further development of idasanutlin plus temozolomide in clinical trials for
neuroblastoma.
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(BD Biosciences, Oxford, UK) and Western analysis carried
out as previously described.21 Human MIC-1 assays were per-
formed according to manufacturer’s protocols (R&D Systems).
IHC was performed using validated protocols and the Ven-
tana Benchmark Ultra automated system (Ventana Medical
Systems, Inc, Tucson, AZ, USA) in the Cellular Pathology
Department, Royal Victoria Infirmary, Newcastle upon
Tyne, UK.
Pharmacokinetic analyses
Chromatographic separation of idasanutlin was achieved
using a Prominence high-performance liquid chromatography
system (Shimadzu, Kyoto, Japan) with a Kinetex C18 50 mm
x 4.6 mm 2.6 μm and a SecurityGuard cartridge C18 3 mm
guard column (Phenomenex, California, USA) and an
API4000 triple quadruple liquid chromatography-mass spec-
trometry (LC–MS/MS) (Applied Biosystems, California, USA;
Supporting Information; Table S1). Aliquots of 20 μL plasma
or tumour homogenate were used for analysis. PK data were
analysed via non-compartmental analysis using WinNonlin
6.3 (Pharsight, Princeton, NJ, USA).
RNA-Seq
NB1691 cells were treated for 24 h and 72 h with 1x their
respective 72 h GI50 concentrations for idasanutlin (41 nM)
and temozolomide (868.1 μM),10 both alone and in combina-
tion, or an equal volume of DMSO. Experiments were per-
formed in triplicate. Total RNA was extracted using RNeasy
Mini kit (Qiagen, Hilden, Germany) and RNA quantity and
integrity assessed using the Agilent Bioanalyzer with RNA
6000 Nano Kit according to the manufacturer’s instructions.
RNA-Seq was performed by Eurofins Genomics (Ebersberg,
Germany). In brief, libraries were prepared using the Illu-
mina TruSeq Stranded mRNA Library Prep Kit and
sequenced at 2 x 100 bp using the Illumina HiSeq 2500 with
v4 chemistry to achieve 30 M paired end reads per sample
(NCBI GEO accession number: GSE104917). Reads were
aligned against transcripts and gene level counts obtained
using Salmon (https://combine-lab.github.io/salmon/) and R
package tximport, respectively. Differential expression analy-
sis was carried out using R package DESeq2. Gene Ontology
analyses were conducted using The Database for Annotation,
Visualisation and Integrated Discovery (DAVID) v6.8.22
Gene Set Enrichment Analysis (GSEA) using MSigDB h.all.
v6.0.symbols.gmt [Hallmarks] was performed on minimally
filtered preranked gene lists based on Log2 fold change rela-
tive to the relevant DMSO time point control.23 Gene sets
with a false discovery rate (FDR) <25% and nominal (NOM)
p value <0.05 were considered significant and enrichment
plots visually inspected. Venn diagrams were generated using
http://bioinformatics.psb.ugent.be/webtools/Venn/ to identify
common gene sets between treatment conditions.
Statistical analyses
All statistical tests were 2-sided and performed using Graph-
Pad Prism v6.0 software with p < 0.05 taken as the level of
significance.
Results
Idasanutlin synergises with temozolomide in SHSY5Y-Luc
and NB1691-Luc neuroblastoma cells in vitro
To extend our previous in vitro observations of synergy
between idasanutlin and temozolomide in a panel of 5 neuro-
blastoma cell lines10 into an orthotopic in vivo model of
neuroblastoma, retrovirally transduced luciferase-tagged
SHSY5Y-Luc and NB1691-Luc, which can be readily detected
using bioluminescence imaging, were generated. Both parental
SHSY5Y and NB1691 cells have previously been shown to
express high protein levels of O6-methylguanine-DNA
methyltransferase (MGMT), which is associated with resis-
tance to temozolomide.10,24 Similar MGMT levels (Fig. S2,
Supporting Information), sensitivities to idasanutlin and
temozolomide (Fig. 1a), and idasanutlin induced p53 pathway
activation were confirmed in SHSY5Y-Luc and NB1691-Luc
cells as parental cells (Fig. 1b, c). Furthermore, median-effect
analysis was performed in vitro in SHSY5Y-Luc (Fig. 1d) and
NB1691-Luc cells (Fig. 1e) and confirmed the previously
reported synergistic interaction between idasanutlin and
temozolomide in parental SHSY5Y and NB1691 cells, with
comparable combination index (CI) values.10
Pharmacokinetic profiling of RO6839921 in a TP53 wt
orthotopic model of neuroblastoma
Initial PK profile analysis of RO6839921 was conducted in
SHSY5Y-Luc orthotopic tumour bearing mice treated intrave-
nously with a single dose of RO6839921 (equivalent to
100 mg/kg of active idasanutlin). Plasma samples were
harvested at 15 min, 30 min, 1 h, 3 h, 6 h and 24 h post-treat-
ment, with tumours also harvested at 3, 6 and 24 h post-treat-
ment. In addition, analyses of plasma and tumour samples
harvested 24 h after a single dose of temozolomide or
RO6839921 and temozolomide in combination were per-
formed, in order to assess any unexpected interactions between
RO6839921 and temozolomide.
Detection of free idasanutlin showed increasing plasma ida-
sanutlin levels over time, with peak levels observed 1 h post-
treatment (Cmax = 133  7 μg/mL), before returning almost to
baseline by 24 h (0.1  0.04 μg/mL), with a half-life of
3.2  0.5 h (Fig. 2a; Table 1). The highest tumour idasanutlin
levels were detected 3 h post-treatment (18.2  2.3 μg/mL),
decreasing to approximately half by 6 h (9.3  1.6 μg/mL) and
returning almost to baseline by 24 h (0.16  0.1 μg/mL)
(Fig. 2b). In line with plasma and tumour concentrations
of RO6839921 alone at 24 h, similar minimal levels of idasanu-
tlin were detected in plasma and tumour samples harvested
24 h post-treatment with RO6839921 and temozolomide
in combination. No idasanutlin was detected in plasma or
3148 Preclinical evaluation of RO6839921 in neuroblastoma
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Figure 1. The effect of idasanutlin alone and in combination with temozolomide in parental and luciferase transduced neuroblastoma cell lines. (a)
72 h GI50 concentrations of parental and luciferase-tagged cell lines to idasanutlin and temozolomide. Values represent the mean of n = 3 SEM. * as
previously reported in Ref. 10. Western analysis for activation of the p53 pathway in (b) SHSY5Y and SHSY5Y-Luc cells, and (c) NB1691 and NB1691-Luc
cells treated for 24 h with 1× and 10× their respective idasanutlin GI50 concentrations. D, DMSO treated control cells. Primary antibodies: p53 1:1000
(DO7, Leica Biosystems Ltd), MYCN 1:500 (sc-53,993, Santa Cruz Biotechnology Inc., Dallas, TX, USA), MDM2 1:200 (OP46, Merck), p21WAF1 1:200
(OP64, Merck), and GAPDH 1:500 (sc-25,778, Santa Cruz Biotechnology Inc). Growth inhibition curves of (d) SHSY5Y-Luc and (e) NB1691-Luc exposed
to idasanutlin and temozolomide alone and in combination at the indicated constant 1:1 ratios relative to their respective GI50 concentrations for 72 h.
Data are shown as the average of at least 3 independent experiments and error bars represent SEM. CI values are shown for each constant ratio
combination and also at ED50, ED75, and ED90. CI range: < 0.1 very strong synergism; 0.1–0.3 strong synergism; 0.3–0.7 synergism; 0.7–0.85moderate
synergism; 0.85–0.9 slight synergism; 0.9–1.1 nearly additive; 1.1–1.2 slight antagonism; 1.2–1.45moderate antagonism; 1.45–3.3 antagonism;
3.3–10 strong antagonism; > 10 very strong antagonism. RG, idasanutlin; TMZ, temozolomide; RG + TMZ, idasanutlin and temozolomide.
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Figure 2. PK and PD analysis of RO6839921 in SHSY5Y-Luc orthotopic tumour bearing mice. PK analysis of active idasanutlin levels using
LC–MS in (a) plasma and (b) tumours harvested at the indicated time points from SHSY5Y-Luc tumour bearing mice treated with a single
dose of RO6839921 (equivalent to 100 mg/kg of active idasanutlin). PD profiling for (c) induction of the p53 pathway using Western
analysis of p53, p21, and MDM2 levels in tumours, and MIC-1 levels in (d) plasma and (e) tumours harvested at the indicated time points
from SHSY5Y-Luc tumour bearing mice after a single dose of RO6839921 (equivalent to 100 mg/kg of active idasanutlin), temozolomide
(34 mg/kg) or RO6839921 and temozolomide. n = 3 mice per time point/group. CTR, control; RG, RO6839921; TMZ, temozolomide; R + T,
RO6839921 and temozolomide. Primary antibodies: p53 1:1000 (#9282, Cell Signalling), MDM2 1:500 (sc-813, Santa Cruz Biotechnology
Inc), p21 1:1000 (#2947, Cell Signalling) and GAPDH 1:500 (sc-25,778). Statistically significant differences were determined by one-way
analysis of variance (ANOVA) with Bonferroni post-hoc tests and paired testing vs. control. p ≤ 0.05 (*); 0.01 (**); 0.001 (***);
0.0001 (****).
3150 Preclinical evaluation of RO6839921 in neuroblastoma
Int. J. Cancer: 144, 3146–3159 (2019) © 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf
of UICC
C
an
ce
r
T
h
er
ap
y
an
d
P
re
ve
n
ti
o
n
tumour samples taken 24 h post-treatment with temozolomide
alone as expected.
RO6839921 induces activation of the p53 pathway in a
TP53 wt orthotopic model of neuroblastoma
Inhibition of the interaction between MDM2 and p53 leads to
stabilisation of p53 and subsequent p53 mediated transcrip-
tional upregulation of downstream target genes such as p21,
MDM2 and MIC-1. PD profiling of RO6839921 was therefore
conducted on plasma and tumour samples harvested at 3, 6
and 24 h post-treatment using Western analysis for p53, p21
and MDM2, and MIC-1 ELISA assays (Fig. 2c–e). Tumour
analysis showed maximal p53 stabilisation from 3 h, sustained
until 6 h post-treatment, with peak induction of both MDM2
and p21 at 6 h, and all levels returning almost to baseline by
24 h (Fig. 2c). Consistent with the latter, a marginal increase
in p53 above baseline with no p21 or MDM2 induction was
observed in samples harvested 24 h post-treatment with temo-
zolomide alone and the combination (Fig. 2c).
MIC-1 is a secreted protein generated from a transcrip-
tional target gene of p53, and thus readily detectable in blood.
Elevated serum MIC-1 levels have previously been shown to
be a potential surrogate PD biomarker of MDM2 inhibitor
activity in RG7112 and idasanutlin clinical trials.25–27 Plasma
and tumour samples were analysed using a human MIC-1
ELISA assay, therefore any detected MIC-1 is tumour specific
(Fig. 2d, e). In plasma, MIC-1 levels were unchanged at 3 h,
peaked at 6 h and returned almost to baseline by 24 h post-
treatment. No elevation of MIC-1 levels was detected in
plasma samples harvested 24 h post-treatment with temozolo-
mide alone, and MIC-1 levels in samples harvested 24 h post-
treatment with RO6839921 and temozolomide were slightly
lower than those observed in 24 h RO6839921 alone samples
(Fig. 2d). In tumour samples, elevated MIC-1 levels were
detected from 3 h post-treatment, peaked at 6 h and decreased
slightly by 24 h. No elevated MIC-1 levels were detected in
tumour samples harvested 24 h post-treatment with temozolo-
mide alone. MIC-1 levels in tumour samples harvested 24 h
post-treatment with RO6839921 and temozolomide were
comparable to the 24 h RO6839921 alone samples (Fig. 2e).
Peak MIC-1 plasma and tumour levels observed at 6 h
post-treatment are consistent with the peak MDM2 and p21
induction observed by protein analysis (Fig. 2c).
RO6839921 in combination with temozolomide induces
tumour growth inhibition and an increase in lifespan
The efficacy of RO6839921 alone and in combination with
temozolomide was assessed in SHSY5Y-Luc and NB1691-Luc
orthotopic tumour bearing mice. The intermittent schedule
used is equivalent to one cycle of treatment over a 3 week
period (Fig. S1, Supporting Information). Mice were rando-
mised into control, RO6839921 (once per week for 3 weeks),
temozolomide (daily x5/3 weeks; consistent with the currently
used clinical dosing schedule in the BEACON Trial
(NCT02308527)), or RO6839921 and temozolomide treatment
groups (n = 8/group; Fig. S1, Supporting Information). No
weight loss was observed for the duration of treatment sug-
gesting all treatments were well tolerated (Fig. S3A, B, Sup-
porting Information).
Twenty-four hours after completion of one treatment cycle,
3 mice per group were sacrificed and plasma and tumours
harvested for PK and PD analyses (Fig. 3; Fig. S1, Supporting
Information). Plasma idasanutlin levels were comparable to
initial PK data (Fig. 2a; Fig. S3C, Supporting Information). In
SHSY5Y-Luc tumour bearing mice, although the combination
treatment led to the greatest increase in plasma MIC-1 levels,
the variation between the triplicates was large possibly as a
consequence of the small sample size (Fig. 3a). Interestingly,
in contrast NB1691-Luc tumour bearing mice, RO6839921
alone led to the greatest and most statistically significant
increase in plasma MIC-1 levels (Fig. 3b).
In addition, immunohistochemical analysis of harvested
SHSY5Y-Luc and NB1691-Luc orthotopic tumours was per-
formed to determine histology and assess treatment induced
effects on the p53 pathway, proliferation and apoptosis
(Fig. 3c–e). Both SHSY5Y-Luc and NB1691-Luc orthotopic
tumours were histologically comparable with poorly differenti-
ated human neuroblastoma (Fig. S3D, E, Supporting Informa-
tion). In NB1691-Luc tumours, both RO6839921 alone and in
combination with temozolomide led to a statistically signifi-
cant reduction in Ki67 positive cells vs. control (Fig. 3c, d). In
contrast, temozolomide treatment alone did not reduce Ki67
immunostaining (Fig. 3c, d). RO6839921 and temozolomide
alone and in combination all resulted in significant increases
in p53 positive cells. RO6839921 and temozolomide alone
induced increases in p21 positivity, with combination treat-
ment resulting in the greatest and statistically significant
increase (Fig. 3c, d). In SHSY5Y-Luc tumours although
RO6839921 alone and in combination with temozolomide led
to a decrease in Ki67 staining this was not statistically signifi-
cant (Fig. 3e). There was an increase in p53 positivity in
response to RO6839921 alone and in combination with temo-
zolomide, but only the latter was statistically significant
(Fig. 3e). In contrast, a statistically significant increase in p21
positivity was observed in response to all treated groups
Table 1. Idasanutlin pharmacokinetic parameters after administration
of a single dose of RO6839921 (equivalent to 100 mg/kg)
Mouse
Cmax
(mg/L)
AUClast
(h*mg/L)
AUCinf
(h*mg/L) T1/2 (h)
1 141 326 327 2.9
2 128 295 295 3.0
3 141 280 281 3.7
Mean 133 300 301 3.2
Standard Deviation 7 24 23 0.5
A minimum of three data points were used to calculate λz with uniform
weighting. Area under the curve (AUC) was calculated using the linear
trapezoidal method.
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Figure 3. MIC-1 levels and IHC analysis of Ki67, p53, p21, and cleaved caspase 3 (CC3) in orthotopic tumours in response to one cycle of
RO6839921 and temozolomide alone and in combination. Plasma MIC-1 levels in untreated and treated (a) SHSY5Y-Luc and (b) NB1691-Luc
orthotopic tumour bearing mice taken 24 h after the last day of treatment. MIC-1 levels were normalised to tumour weight, to account for
variations in tumour size in response to treatment. Statistically significant differences vs. control were determined by unpaired t-tests.
(c) Representative images captured using the Aperio FL Digital Pathology Slide Scanner of Ki67 (Dako, Agilent, Stockport, UK), p53 (Bp53-11,
Ventana Medical Systems, Inc), p21 (OP64; Merck Millipore, Watford, UK), and CC3 (MAB835; R&D Systems, Abingdon, UK) stained 5 μm
thick formalin-fixed, paraffin embedded NB1691-Luc tumour sections. Scale bar = 200 μm. Graphical representation of quantification of %
positive Ki67, p53, p21, and CC3 staining in (d) NB1691-Luc and (e) SHSY5Y-Luc orthotopic tumours using Imagescope software and
algorithms (Leica Biosystems, Newcastle upon Tyne, UK) and/or scored for positive immunostaining by a consultant pathologist (KW).
n = 3 mice per group. All data are shown as the mean and error bars represent SEM. CTR, control; RG, RO6839921; TMZ, temozolomide;
R + T, RO6839921 and temozolomide. Statistically significant differences were determined by one-way ANOVA with Bonferroni post-hoc
tests and paired testing vs. control. p ≤ 0.05 (*); 0.01 (**); 0.001 (***); 0.0001 (****). [Color figure can be viewed at wileyonlinelibrary.com]
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(Fig. 3e). The overall positivity for cleaved caspase-3 across all
treatment groups in both models was low (≤5%) and
remained relatively unchanged despite increases in p53 stain-
ing (Fig. 3c–e). This is in contrast to our previous in vitro
observations of higher caspase 3/7 activity in response to
single agent and combination treatment. Additional γ-H2AX
(p-serine 139) was performed as an indicator of DNA frag-
mentation and apoptosis.28 The results showed that all treat-
ments resulted in increased γ-H2AX IHC staining vs. control,
however only RO6839921 alone led to a statistically significant
increase in NB1691-Luc tumours and temozolomide alone led
to a statistically significant increase in SHSY5Y-Luc tumours
(Fig. S4A,B, Supporting Information). In contrast, a greater
induction of γ-H2AX (p-serine 139) was observed in SHSY5Y
cells treated in vitro with idasanutlin and temozolomide in
combination than either agent alone (Fig. S4C, Supporting
Information). Taken together the differences between in vitro
and in vivo observations suggest it is possible that the time-
point at which tumours were harvested was suboptimal for
detection of apoptosis by IHC and earlier timepoints may
have been more informative.
Efficacy of RO6839921 and temozolomide alone and in
combination on tumour growth were monitored by biolumi-
nescence imaging, tumour weight, survival and treatment
induced %ILS (Fig. 4; Table 2; Fig. S1, Supporting Informa-
tion). After 1 week of treatment (Day 8/BLI1), a 52%
reduction in bioluminescence vs. control was observed in
SHSY5Y-Luc tumour bearing mice treated with RO6839921,
36% for temozolomide alone and 63% for the combination,
where the latter led to the greatest and most statistically sig-
nificant reduction (Fig. 4a). A similar reduction in biolumi-
nescence was observed after 2 weeks of treatment (Day
15/BLI2); 49% for RO6839921 alone, 39% for temozolomide
alone and 66% for the combination, with all treatments pro-
ducing statistically significant differences and the combination
treatment again leading to the greatest and most significant
reduction (Fig. 4a; Fig. S5, Supporting Information). In
NB1691-Luc tumour bearing mice, after 1 week of treatment
(Day 8/BLI1), a 9% reduction in bioluminescence vs. control
was observed for RO6839921 alone, 35% for temozolomide
alone and 29% for the combination, although none were sta-
tistically significant (Fig. 4b). In contrast, after 2 weeks of
treatment (Day 15/BLI2), a 29% reduction in bioluminescence
was observed for RO6839921 alone, 24% for temozolomide
alone and 55% for the combination, where the latter led to the
greatest and a statistically significant reduction compared to
control (Fig. 4b; Fig. S5, Supporting Information). In addition,
after 2 weeks of treatment (Day 15/BLI2), the combination
also led to statistically significant reductions (unpaired t-test,
p < 0.05) in bioluminescence in both SHSY5Y-Luc and
NB1691-Luc models vs. temozolomide alone.
In line with bioluminescence results, assessment of tumour
weight harvested 24 h after the last treatment demonstrated
the combination treatment led to the greatest and a
statistically significant reduction in tumour weight in both
SHSY5Y-Luc (64% reduction; Fig. 4c) and NB1691-Luc (57%
reduction; Fig. 4d) orthotopic models compared to control.
However, tumour weight reduction after combination treat-
ment vs. temozolomide alone did not reach statistical signifi-
cance in either model. MYCN amplified NB1691-Luc cells
grew more rapidly and formed larger orthotopic tumours
compared to non-MYCN amplified SHSY5Y-Luc cells consis-
tent with MYCN amplified disease (Fig. 4c,d). No macroscopic
metastases were observed in either model.
Finally, SHSY5Y-Luc and NB1691-Luc tumour bearing
mice were monitored for survival to humane endpoint, and
treatment induced increases in life span (% ILS) vs. control
determined in the remaining n = 5/group (Fig. 4e, f; Table 2,
Fig. S1, Supporting Information). In the SHSY5Y-Luc model,
both RO6839921 alone (p < 0.05) and in combination
(p < 0.005) led to significant increases in survival vs. control
(Fig. 4e), whereas in the NB1691-Luc model, RO6839921 and
temozolomide alone and in combination all led to significant
increases in survival (p < 0.005; Fig. 4f ). Percentage ILS based
on median survival vs. control was 14% for both RO6839921
and temozolomide alone, and 23% for the combination in the
SHSY5Y-Luc orthotopic model (Table 2). In the NB1691-Luc
orthotopic model, %ILS vs. control was 6% for temozolomide
alone and 23% for both RO6839921 alone, and the combina-
tion. Although in the NB1691-Luc model there was no differ-
ence in median survival between RO6839921 alone and the
combination, NB1691-Luc tumour bearing mice treated with
the combination survived the longest (Fig. 4f ), and compari-
son of %ILS based on mean survival was 16% for RO6839921
alone vs. 31% for combination treatment (Table 2).
Idasanutlin and temozolomide act through activation of the
p53 pathway and inhibition of MYC targets
To identify potential pathways and mechanisms involved
in idasanutlin and temozolomide combination treatment,
RNA-Seq was performed on NB1691 cells treated with idasa-
nutlin and temozolomide alone and in combination for 24 h
and 72 h. Differential gene expression analysis showed that
idasanutlin alone resulted in the greatest number of differen-
tially expressed genes vs. DMSO control at 24 h post-treat-
ment, while the combination resulted in the greatest number
at 72 h post-treatment (Fig. 5a). Temozolomide alone led to
the smallest number of differentially expressed genes vs.
DMSO at both time points (Fig. 5a). Consistent with this,
analyses to determine the similarity between treatment sam-
ples showed clustering of idasanutlin with the combination,
and DMSO control with temozolomide (Fig. S6, Supporting
Information). Gene ontology analysis demonstrated that the
combination led to upregulation of genes involved in p53,
apoptosis and signal transduction and downregulation of
genes involved in DNA replication, mitosis, cell cycle progres-
sion and cell division (Fig. 5b and Fig. S7A, Supporting
Information).
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GSEA of idasanutlin treated NB1691 cells similarly con-
firmed upregulation of genes involved in the p53 pathway and
also revealed downregulation of MYC targets and genes
involved in metabolism and MTORC1 signalling (Fig. 5c and
Fig. S7B, Supporting Information). Comparison of overlapping
gene sets between single and combination treatments at 24 h
and 72 h post-treatment are shown in Figure 5d. This revealed
that both idasanutlin and temozolomide led to upregulation of
the p53 pathway and downregulation of MYC target genes at
24 h and 72 h (Fig. 5c–f and Fig. S7B-D, Supporting
Figure 4. Efficacy of one cycle of RO6839921 alone and in combination with temozolomide in SHSY5Y-Luc and NB1691-Luc orthotopic tumour
bearing mice. Graphical representation of bioluminescence emission of untreated (CTR) and treated (a) SHSY5Y-Luc and (b) NB1691-Luc
orthotopic tumour bearing mice on Day 8 (BLI 1) and Day 15 (BLI 2) of treatment with RO6839921 alone (RG), temozolomide alone (TMZ) or
RO6839921 and temozolomide in combination (R + T). n = 8 mice per group. Statistically significant differences vs. control were determined
by unpaired t-tests. Weight of tumours from untreated and treated (c) SHSY5Y-Luc and (d) NB1691-Luc orthotopic tumour bearing mice taken
24 h after the last day of treatment. n = 3 mice per group. All data points are shown as the mean and error bars represent SEM. Statistically
significant differences vs. control were determined by unpaired t-tests. Kaplan-Meier plots and log-rank (Mantel-Cox) analysis of survival of
control and treated (e) SHSY5Y-Luc and (f ) NB1691-Luc orthotopic tumour bearing mice. n = 5 mice per group. CTR, control; RG, RO6839921;
TMZ, temozolomide; R + T, RO6839921 and temozolomide. p ≤ 0.05 (*); 0.01 (**); 0.001 (***).
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Information), with additional upregulation of genes involved
in apoptosis and TNFA signalling via NFKB, and downregula-
tion of E2F targets at 72 h (Fig. 5d,g and Fig. S7B-D, Support-
ing Information). These gene sets and pathways are consistent
with the expected pro-apoptotic and anti-proliferative mecha-
nism of action for combining an MDM2 inhibitor with a cyto-
toxic agent. The downregulation of MYC targets is particularly
interesting as NB1691 cells are MYCN amplified, but interest-
ingly MYCN protein levels remained unchanged after 24 h
treatment with idasanutlin alone (Fig. 1c).
Consistent with cluster analysis (Fig. S6B, Supporting
Information), idasanutlin and the combination treatment also
share additional gene sets not observed in response to temozo-
lomide alone, in particular downregulation of genes involved
in MTORC1 signalling was observed at 24 h and 72 h
(Fig. 5c–e and Fig. S7B-D, Supporting Information). Analysis
of gene sets enriched only in the combination treatment
revealed upregulation of IL6-JAK-STAT3 Signalling and
downregulation of genes regulated by Interferon Gamma at
24 h, suggesting a potential cellular stress response and
immune cell modulation (Fig. 5d,e).
In view of the identified cooperative upregulation of the
p53 pathway by idasanutlin and temozolomide by GSEA,
assessment of the differential expression of selected p53 regu-
lated genes of interest showed that overall the combination
led to significantly greater induction than either agent alone at
24 h and 72 h (Fig. 5h and Fig. S7E, Supporting Information).
This includes MIC-1, p21 and MDM2 which are used as PD
biomarkers in studies of MDM2 antagonists, including our
study, as well as pro-apoptotic genes FDXR, BBC3, FAS, BAX
and GADD45A. Similarly, SESN1 and SESN2 increased, both
negative regulators of MTORC1 consistent with the observed
downregulation of MTORC1 Signalling,29 and SERPINE1,
which is involved in, and acts as a marker for replicative
senescence30 (Fig. 5h and Fig. S7E, Supporting Information).
Discussion
Novel therapies to improve survival of high-risk neuroblas-
toma patients are urgently needed. Our study is the first to
evaluate and demonstrate the efficacy of RO6839921, the IV
prodrug of the MDM2 antagonist idasanutlin, as a single
agent and in combination with temozolomide in 2 TP53 wt
orthotopic models of neuroblastoma. This follows on from
our previous extensive in vitro assessment of idasanutlin alone
and in combination with chemotherapies (cisplatin, doxorubi-
cin, topotecan, busulfan and temozolomide) in a panel of
MYCN amplified and non-amplified neuroblastoma cell
lines.10 The intermittent dosing schedule tested showed that
both RO6839921 alone and in combination with temozolo-
mide were well tolerated. However, some MDM2 antagonists
have been reported to display interspecies selectivity, with
reduced binding affinities for mouse and rat MDM2,31 thus
further investigation of RO6839921 based combinations in
suitable toxicity models may be required.
In vivo efficacy data, incorporating a combination of
tumour bioluminescence, tumour weight and survival analyses
in both models, together demonstrated that a single cycle of
RO6839921 was as efficacious as temozolomide alone, and
when used in combination led to the greatest tumour growth
inhibition, as evident by bioluminescence (Day15/BLI2) and
tumour weight reduction, and increase in survival. In compar-
ison to temozolomide alone, the combination resulted in
statistically significant reductions in bioluminescence (Day
15/BLI2) in both models. Minor differences in response to
treatments between the 2 orthotopic models used could
potentially be attributed to MYCN amplification in NB1691
cells which led to in vivo tumours that formed more rapidly
and were larger in size. Taken together, the observed in vivo
efficacy is in keeping with our previous in vitro synergy data
of idasanutlin and temozolomide, with the combination dem-
onstrating clear evidence of activity after only one cycle of
intermittent treatment. For clinical evaluation, multiple cycles
and testing or other dosing schedules are recommended such
as the adult RO6839921 schedule (daily ×5/ 28 day cycles;
NCT02098967).
Our study also provides valuable PK and PD data to support
paediatric clinical trials with an observed PK profile of
RO6839921 consistent with IV administration, and compatible
with recommended intermittent dosing schedules aimed to
enable bone marrow recovery and overcome haematological
toxicities. The PD profile was consistent with the PK profile,
mechanism of action, and previous studies.11,25,27,32 The
Table 2. Percentage increase in lifespan (ILS) of SHSY5Y-Luc and NB1691-Luc orthotopic tumour bearing mice in response to treatment with
RO6839921 and temozolomide alone and in combination
Cell line Median/Mean/%ILS Control RO6839921 Temozolomide RO6839921 + temozolomide
SHSY5Y-Luc Median Survival (Day) 43 49 49 56
%ILS (Median) - 14% 14% 30%
Mean Survival (Day) 44 49 49 54
%ILS (Mean) - 12% 11% 24%
NB1691-Luc Median Survival (Day) 35 43 37 43
%ILS (Median) - 23% 6% 23%
Mean Survival (Day) 35 41 41 46
%ILS (Mean) - 16% 16% 31%
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Figure 5. RNA-Seq analysis of NB1691 cells treated with idasanutlin and temozolomide alone and in combination. (a) Graph showing the number
of statistically significant and greater than two-fold differentially expressed genes in response to idasanutlin and temozolomide alone and in
combination for 24 h and 72 h. (b) Top 3 DAVID GO biological processes up- and downregulated in response to idasanutlin and temozolomide in
combination for 24 h. (c) Enriched Hallmark gene sets identified using GSEA for genes up- and downregulated in NB1691 cells in response to
idasanutlin for 24 h vs. DMSO. NES, Normalised Enrichment Score. Red arrows indicate gene sets common to all treatment conditions at 24 h.
(d) Venn diagrams showing the overlap of gene sets enriched in the different treatment conditions at 24 h (top) and 72 h (bottom). (e) Enriched
Hallmark gene sets identified using GSEA for genes up- and downregulated in NB1691 cells in response to idasanutlin and temozolomide in
combination for 24 h. Red arrows indicate gene sets common to all treatment conditions at 24 h. GSEA gene set enrichment plots showing
(f) positive enrichment of the p53 Pathway and negative enrichment of MYC Targets v1 and (g) positive enrichment of TNFA Signalling via NFKB and
negative enrichment of E2F Targets in NB1691 cells treated with idasanutlin and temozolomide in combination for 72 h. (h) Graph showing the
Log2 fold change in expression relative to DMSO control of selected p53 regulated genes of interest in NB1691 cells in response to idasanutlin and
temozolomide alone and in combination for 24 h. Statistical significance was determined using unpaired t-tests p ≤ 0.05 (*); 0.01 (**); 0.001
(***); 0.0001 (****); ns, not significant; RG, idasanutlin; TMZ, temozolomide; RG + TMZ, idasanutlin and temozolomide. [Color figure can be
viewed at wileyonlinelibrary.com]
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analysis of PD biomarkers of response to RO6839921 alone
showed changes in MIC-1, p21, p53 and Ki67, consistent with
our previous in vitro observations of idasanutlin mediated
anti-tumour activity.10 Our study is the only preclinical study
of idasanutlin in neuroblastoma so far to include MIC-1 as a
PD biomarker, and demonstrated that in response to combina-
tion treatment MIC-1 was the most responsive biomarker in
the SHSY5Y-Luc model and p21 in the NB1691-Luc model.
RNA-Seq analysis of NB1691 cells in vitro showed the greatest
induction of MIC-1 expression in response to combination
treatment compared to either idasanutlin or temozolomide
alone. Since circulating MIC-1 is not tumour specific, we rec-
ommend that future studies continue to include a panel of PD
biomarkers for proof-of-mechanism and response, ideally
including p21 tumoural or circulating tumour cell expression as
recently reported by us (Merugu et al, submitted).
We previously conducted similar PK/PD analyses of orally
formulated idasanutlin in preliminary studies of a subcutane-
ous NGP neuroblastoma xenograft model after a single oral
dose equivalent to 100 mg/kg of active idasanutlin (Fig. S8,
Supporting Information). Comparison of the present
RO6839921 PK and PD data with orally formulated idasanu-
tlin demonstrates that consistent with the route of administra-
tion and previous literature,4 RO6839921 led to a much
higher plasma concentration of active idasanutlin (>100 μg/
mL vs. 5 μg/mL). Moreover, PD analysis showed a more
consistent and robust induction of PD biomarkers in response
to RO6839921 compared to oral idasanutlin, at least partly as
a result of the higher achievable plasma concentrations. These
data therefore provide support for the superior PK profile and
activity of RO6839921.
High MGMT levels are usually the primary cause of temo-
zolomide resistance, with deficient MMR also playing a role.33
The role of p53 in temozolomide sensitivity has not been fully
elucidated, however p53 is known to be involved in MMR and
the DNA damage response and has previously been shown to
induce downregulation of MGMT through sequestration of
the Sp1 transcription factor.34,35 Although no decrease in
MGMT mRNA levels in response to idasanutlin was observed
in our study, a decrease in MGMT protein levels was observed
and suggests post-translational mechanisms (Fig. S9, Support-
ing Information). GSEA revealed that idasanutlin and temozo-
lomide act cooperatively to upregulate the p53 pathway and
downregulate MYC targets, the former resulting in signifi-
cantly greater induction of several apoptotic genes. Further-
more, the data also revealed idasanutlin mediated
downregulation of MTORC1 signalling which has previously
been linked to chemoresistance and could therefore sensitise
cells to temozolomide. However, a recent Phase II trial of
irinotecan-temozolomide with temsirolimus in children with
refractory/relapsed neuroblastoma did not observe outcomes
meriting further study.36 A recent study has reported potent
preclinical efficacy combining the MTORC1 inhibitor temsiro-
limus with idasanutlin in neuroblastoma preclinical models.12
Temozolomide has previously been reported to be a substrate
of MDR-1, which is expressed at high levels in both SHSY5Y
and NB1691 cells and we have previously reported that at very
high concentrations idasanutlin is able to modulate MDR-1
function.21,37 Taken together, these provide potential mecha-
nisms by which MDM2 antagonists enhance temozolomide
mediated cytotoxicity, consistent with the observed efficacy of
RO6839921 combined with temozolomide.
An increasing number of targeted agents are now entering
early phase paediatric trials including the lead Novartis
MDM2 antagonist, HDM-201, as part of the Next Generation
Personalised Neuroblastoma Therapy (NEPENTHE) trial
(NCT02780128) and the dual MDM2/MDMX inhibitor
ALRN-6924 (NCT03654716). Additionally, Alisertib (Aurora
kinase A) and Crizotinib (ALK) have progressed to Phase I/II
trials in combination with chemotherapy in neuroblastoma
patients38–40 and the benefit of incorporating Crizotinib to
upfront standard therapy for patients with newly diagnosed
high-risk neuroblastoma will be evaluated in an upcoming
Phase III trial (NCT03126916). Full results from the recently
completed Phase I trial of RO6839921 in adults with advanced
solid tumours and AML are pending (NCT02098967). How-
ever, interim data from the advanced solid tumour arm of the
trial show that RO6839921 was generally well tolerated and
main dose limiting toxicities observed were thrombocytopenia
and neutropenia, in line with adult trial data for oral idasanu-
tlin, as well as other MDM2 inhibitors.16,41–43 Gastrointestinal
toxicity was reported but not dose limiting as previously
reported with oral Idasanutlin.15,16 The current emphasis is
on the development of the oral formulation of idasanutlin,
which in comparison to the IV formulation, is at a later stage
of development (Phase 3 in AML). Temozolomide is currently
used as standard backbone chemotherapy regimens for
relapsed and refractory neuroblastoma and has been shown to
be generally well tolerated. Clinical data in children have
reported thrombocytopenia and neutropenia as the main
toxicities.44–47 Taken together with the above reported toxic-
ities for RO6839921 and idasanutlin,15,16 potential toxicities
for RO6839921/idasanutin with temozolomide are anticipated
to be haematological and gastrointestinal, but manageable,
particularly if temozolomide is used at the lower combination
regimen dose of 100 mg/m2.
Based on our previous in vitro assessment of idasanutlin10
and in line with the inclusion criteria for current clinical trials
of MDM2 inhibitors, we recommend that selection of patients
be based on the presence of wt TP53, however patient p14ARF
and MDM2 status should be recorded. Baseline tumour
MDM2 expression may be important as clinical response to
idasanutlin in AML patients has been associated with baseline
MDM2 expression in leukaemic blasts.48 In conclusion, our
study provides valuable PK, PD and efficacy data of IV
RO6839921 as well as potential mechanisms of synergy to
support the paediatric assessment of IV or oral idasanutlin,
alone and in combination with a temozolomide backbone to
Chen et al. 3157
Int. J. Cancer: 144, 3146–3159 (2019) © 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf
of UICC
C
an
ce
r
T
h
er
ap
y
an
d
P
re
ve
n
ti
o
n
provide a novel therapeutic strategy for patients with
relapsed/refractory high-risk neuroblastoma.
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